Therapeutic sentinel lymph node imaging.
Improving existing means of sentinel lymph node identification in non-small cell lung cancer will allow for molecular detection of occult micrometastases that may cause recurrence in early stage non-small cell lung cancer. Furthermore, targeted application of chemical and biological cytotoxic agents can potentially improve outcomes in patients with lymph node (LN) metastases. "Therapeutic Sentinel Lymph Node Imaging" incorporates these modalities into a single agent thereby identifying which LNs harbor tumor cells and simultaneously eradicating metastatic disease. In this review, we summarize the novel preclinical agents for identification and treatment of tumor bearing LNs and discuss their potential for clinical translation.
Kachala
Stefan S
SS
Division of Thoracic Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.
Servais
Elliot L
EL
Park
Bernard J
BJ
Rusch
Valerie W
VW
Adusumilli
Prasad S
PS
D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy*; D003952:Diagnostic Imaging / Q000379:methods; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000556:secondary / Q000628:therapy*; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging; D018579:Patient Selection; D011237:Predictive Value of Tests; D016896:Treatment Outcome